Global High-Priority Regulatory Events — March 10, 2026

10-03-2026

Unknown Company filed an Open Offer on March 10, 2026. The content of the filing is largely garbled and unreadable, preventing extraction of specific details such as acquirer information, offer price, or target shares. No financial metrics, period comparisons, or performance data are available.

• ·Filing Type: Open Offer
• ·Filing Date: March 10, 2026

10-03-2026

Morarjee Textiles Limited, under Corporate Insolvency Resolution Process (CIRP) of the Insolvency and Bankruptcy Code 2016, has notified stock exchanges of its Thirty Fifth Committee of Creditors (COC) meeting scheduled for 10 March 2026 at 3:00 p.m. The company's affairs are managed by Resolution Professional Mr. Ravi Sethia, appointed by NCLT Mumbai on 09 February 2024 and confirmed by COC on 22 May 2024. This ongoing insolvency process signals continued financial distress with no resolution or operational updates provided.

• ·NCLT order: CP(IB) No. 1318/MB-VI/2022 dated 09 February 2024.
• ·Company CIN: L52322MH1995PLC090643.
• ·Compliance pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 and Schedule III Clause A Part A sub-clause 16(g).

10-03-2026

Resolution Professional Umesh B. Sonkar provided post-facto intimation of the 7th Meeting of the Committee of Creditors (CoC) for Reliance Home Finance Limited (under CIRP), held on March 9, 2026, at 03:30 P.M. IST via video conferencing. This follows the CIRP initiation intimated on September 20, 2025. No outcomes, decisions, or financial details from the meeting were disclosed.

• ·BSE Scrip Code: 540709
• ·NSE Symbol: RHFL
• ·ISIN: INE217K01011
• ·RP Registration: IBBI/IPA-001/IP-P-02619/2021-2022/14043 (valid upto December 31, 2026)
• ·CIRP initiation reference intimation: September 20, 2025

10-03-2026

Mahamaya Lifesciences Limited's Board approved via circular resolution on March 10, 2026, rescheduling the utilization of unutilised IPO proceeds of ₹3,449.03 L (₹34.49 Cr) up to March 31, 2028, with no change in the original objects from the November 14, 2025 Prospectus. Out of the proposed ₹6,196.43 L (₹61.96 Cr) from net IPO proceeds, only ₹2,747.40 L (₹27.47 Cr) has been utilized as of February 28, 2026, representing partial deployment amid execution delays. The rescheduling accounts for factors like limited FY 2025-26 window post-November 2025 receipt, sequential project stages for the new Technical Manufacturing Plant, and procurement cycles, while funds remain parked in compliant instruments.

• ·IPO proceeds received in November 2025
• ·Unutilised proceeds parked in permitted interest-bearing instruments
• ·Continued monitoring and disclosure per Regulation 32 of SEBI LODR, including Audit Committee review and Monitoring Agency reporting
• ·No variation in project scope, configuration, intended capacity, or overall utilisation

10-03-2026

Craig Abrahams notified Playtika Holding Corp. of his resignation as President and Chief Financial Officer, effective April 1, 2026, with no relation to financial issues or disagreements. The board appointed Tae Lee as acting Chief Financial Officer and principal financial officer effective the same date, and updated Robert Antokol's title to Chief Executive Officer, President, and Chairperson of the Board. No changes to Antokol's compensation and no material interests or family relationships for the involved parties.

• ·Tae Lee, age 41, previously Corporate Finance Manager at Meta Platforms, Inc. from 2019-2021; MBA from Columbia Business School; BA in Economics from University of Chicago.
• ·Mr. Lee's compensation as acting CFO not yet determined; to be filed as amendment.
• ·Reference to 2025 Proxy Statement filed April 25, 2025, for Antokol's compensation and experience.
• ·No arrangements, understandings, or family relationships for Lee or Antokol; no material interests exceeding $120,000 threshold.

10-03-2026

Bullish reported a net loss of $785M for the year ended December 31, 2025, compared to a profit of $80M in 2024 and $1.3B in 2023, primarily due to a $675M negative change in fair value of digital assets held, net. Digital assets sales declined 2% YoY to $244.8B, with on-exchange volumes down 2% to $244.4B while other venues surged 1,717% to $396M; however, other revenues more than doubled to $159M, driven by liquidity service fees and interest income. Administrative expenses rose 19% to $182M, contributing to the loss, while the company expanded products like crypto options (Q3 2025) and U.S. spot trading (Q4 2025) and secured mandates for 15 new digital asset ETFs.

• ·Cost of digital assets derecognized declined 2% YoY to $244.7B in 2025.
• ·Change in fair value of digital assets held, net: -$675M in 2025 vs +$207M in 2024.
• ·EPS basic: $(5.99) in 2025 vs $0.70 in 2024.
• ·Weighted average shares basic: 127,723 thousand in 2025 vs 112,664 thousand in 2024.
• ·Consensus Hong Kong event held February 2026; flagship North America event scheduled May 2026 in Miami.

10-03-2026

Climate Transition Special Opportunities SPAC I, a Cayman Islands blank check company targeting mergers in climate transition, specialty finance, renewable energy, and regenerative agriculture sectors, filed Amendment No. 3 to its S-1 registration statement for a $150M IPO of 15M units at $10 each, consisting of one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50. Net proceeds before expenses are $141M, with $150M (or $172.5M if over-allotment exercised) to be placed in trust; sponsor holds 5,675,000 founder shares after share split and transfers. No target identified yet, and investing involves high risks as noted in the prospectus.

• ·Warrants exercisable 30 days after initial business combination, expire 5 years post-combination
• ·Underwriting over-allotment option: 45 days from prospectus date
• ·Separate trading of shares and warrants expected on 52nd day post-prospectus
• ·NYSE listing intended: CLSO U (units), CLSO (shares), CLSO WS (warrants)
• ·Sponsor transferred 25,000 founder shares to each independent director (total 75,000) at ~$0.004/share

10-03-2026

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced a $40M private placement financing, expecting gross proceeds from selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant. The financing includes participation from Coastlands Capital, Commodore Capital, Vivo Capital, and other institutional investors, with Leerink Partners as exclusive placement agent. The transaction is expected to close on March 10, 2026, subject to customary conditions.

• ·Pre-funded warrants exercisable immediately at $0.00001 per share until fully exercised, subject to ownership limits.
• ·Private placement conducted per Nasdaq rules, priced at Minimum Price requirement.
• ·AN2 Therapeutics to file SEC registration statement for resale of shares and warrant shares.
• ·Pipeline targets: polycythemia vera, NTM lung disease (M. abscessus), Chagas disease, melioidosis, oncology, infectious diseases.

10-03-2026

U Power Ltd, a Shanghai-based motor vehicle parts manufacturer, filed an F-1 registration statement on March 9-10, 2026, for a public offering of Units at an assumed $1.31 each, including Class A Ordinary Shares and Warrants with price reset provisions (to 70% and 50% of initial exercise price) and zero cash exercise options that could result in up to 21.1M additional shares issued without cash to the company, causing substantial shareholder dilution. The Warrants lack a public market and are exercisable for up to 1 year, with Nasdaq delisting risks highlighted due to dilution concerns, insider ownership, and a proposed $5M minimum market value rule from January 13, 2026. Management has broad discretion over proceeds use, with no assurance of favorable returns.

• ·Warrants exercisable immediately until 1-year anniversary of issuance.
• ·First reset on 4th trading day post-closing; second on 8th trading day.
• ·Nasdaq proposed $5M minimum market value rule (Jan 13, 2026) could trigger immediate suspension/delisting without cure period.
• ·Over-allotment option exercisable within 45 days of prospectus.

10-03-2026

Lipocine Inc. (LPCN) filed its 10-K annual report on March 10, 2026, outlining extensive risk factors including the need for substantial additional capital to fund clinical trials and operations, potential delays in regulatory approvals, and challenges in commercializing TLANDO and product candidates such as LPCN 1154, LPCN 2201, LPCN 2101, LPCN 2203, LPCN 2401, and LPCN 1148. The filing emphasizes uncertainties in achieving profitability, stock price volatility, competition in the TRT market, and risks of delisting from Nasdaq Capital Market. No financial performance data or period-over-period comparisons were detailed in the provided risk factor excerpts.

• ·Risks include FDA Advisory Committee meetings, Phase 4 study commitments, and REMS requirements
• ·Potential for product recalls, withdrawals, or litigation impacting revenues
• ·Anti-takeover provisions in amended certificate of incorporation, bylaws, and stockholder rights plan

10-03-2026

Total assets grew 38% to $1.53M as of January 31, 2026, driven by $446M net proceeds from share issuances that boosted cash and cash equivalents to $0.49M from $0.15M, while total equity rose 44% to $1.41M. However, quarterly sales declined 59% YoY to $20.2k with gross profit down 45% to $10k, amid sharply higher mineral property expenditures up 66% to $23.7k and total operating costs up 54% to $33.6k, leading to an operational loss widening to $23.6k from $3.6k. For the six months, net loss improved 20% to $24.3k from $30.4k, but cash used in operations surged to $72.4k from $20.3k.

• ·Investment in equity securities increased to $84k from $28k.
• ·Equity-accounted investments rose to $60k from $56k.
• ·Current liabilities decreased to $21k from $26k.
• ·Mineral rights and properties slightly up to $713k from $710k.
• ·Net cash used in investing activities $37k vs $136k prior six months.

10-03-2026

Trailblazer Merger Corp I reported a net loss of $8.3M for the year ended December 31, 2025, compared to net income of $0.28M in 2024, primarily due to a $6.2M loss on debt extinguishment and $0.2M loss on fair value changes, despite $0.94M in interest income. Total assets declined 84% YoY to $4.3M from $27.7M, driven by Trust Account reduction to $4.0M from $26.8M amid heavy redemptions of Class A shares (down to 333K shares from 2.4M). Liabilities rose to $16.2M from $7.2M with $11.0M in new convertible promissory notes, worsening stockholders' deficit to $15.9M from $6.1M, while operating costs increased 12% YoY.

• ·Class A redeemable shares at $11.76/share in 2025 (vs $11.19/share in 2024)
• ·Excise tax payable increased to $912,593 from $497,749
• ·Promissory note - related party extinguished; new convertible note $11.0M with related party
• ·Net cash used in operating activities worsened to $2.55M from $1.56M
• ·Cash paid for income taxes $1.04M in 2025 vs $0.35M in 2024

10-03-2026

Arq, Inc. reported revenue growth of 10% YoY to $120.3M in 2025 from $109.0M in 2024, with Adjusted EBITDA improving to $13.2M from $10.5M and SG&A expenses declining 21%. However, net loss widened dramatically to $52.6M from $5.1M, driven by a $44.8M impairment of long-lived assets and a 25% increase in cost of revenue; operating cash flow turned negative at $2.7M versus positive $10.5M prior year. Total assets decreased to $230.6M from $284.4M, reflecting impairments and asset write-downs.

• ·Property, plant and equipment net: $143.2M (2025) vs $178.6M (2024)
• ·Revolving credit facility increased to $19.0M (2025) from $13.8M (2024)
• ·Weighted-average basic shares outstanding: 41,522 (thousands) in 2025 vs 36,051 (thousands) in 2024
• ·Basic loss per share: $(1.27) (2025) vs $(0.14) (2024)

10-03-2026

Creative Media & Community Trust Corp (CMCT) reported total revenues of $116.7M for the year ended December 31, 2025, down 6.3% YoY from $124.5M, with declines in office (-7.6%), multifamily (-19.1%), and lending (-16.7%) segments offsetting hotel growth of 4.9%. Net loss widened 53.7% to $39.6M from $25.8M amid higher expenses (+2.7%) and a $3.7M real estate impairment, though FFO attributable to common stockholders improved to -$31.5M from -$46.3M and total assets stood at $859.2M, down from $889.6M.

• ·Sheraton Grand Hotel (Sacramento, CA) had 72.5% occupancy and $152.70 RevPAR.
• ·Investments in real estate, net: $698.1M (2025) vs. $709.2M (2024).
• ·Loans receivable, net: $0 (2025) vs. $56.2M (2024).
• ·Net loss attributable to common stockholders per share: $(67.08) basic and diluted (2025) vs. $(431.43) (2024).
• ·Weighted average common shares outstanding: 919K basic and diluted (2025) vs. 170K (2024).

10-03-2026

Guided Therapeutics, Inc. completed a Warrant Exchange on March 2, 2026, for eligible warrants from its September 1, 2022 Private Offering, with 4,825,000 warrant shares (22.7% of outstanding eligible warrants) tendered, resulting in $980,000 cash proceeds and issuance of 4,825,000 restricted common shares. Shares outstanding increased from 86,691,976 to 91,516,976, representing about 5.6% dilution. However, participation was low, leaving 16,398,080 eligible warrants outstanding, with expirations in 2026 and 2027.

• ·Eligible warrants originally priced at $0.65 exchanged at $0.25; those at $0.50 at $0.20.
• ·Expiration of Warrant Exchange: February 25, 2026 at 8:00 a.m. ET.
• ·Offer to Exchange dated February 11, 2026.
• ·Of remaining warrants: 11,973,080 expire Sep 1-Oct 18, 2026; 4,425,000 expire Sep 1-Oct 18, 2027.
• ·Shares issued in reliance on Section 3(a)(9) exemption; no commissions paid.

10-03-2026

dMY Squared Technology Group, Inc., Horizon Quantum Holdings Ltd., and Horizon Quantum Computing Pte. Ltd. amended PIPE Subscription Agreements with certain investors, introducing a 'Reduction Right' allowing them to satisfy part of their $111.9M PIPE commitment using dMY Class A common shares owned or purchased in the open market, subject to specific voting and non-redemption conditions, ahead of the Business Combination special meeting. The amendment to the IonQ side letter removes the prior condition requiring a commercial agreement for quantum hardware purchase, facilitating IonQ's participation. No financial declines or flat metrics are reported, but the filing highlights ongoing risks to deal completion.

• ·PIPE Subscription Agreements originally dated December 4, 2025 and March 6, 2026
• ·Amendment to PIPE Agreements and IonQ Side Letter executed March 9, 2026
• ·Reduction Right election deadline: one Business Day prior to dMY stockholder redemption deadline
• ·Business Combination Agreement dated September 9, 2025
• ·Registration Statement effective February 17, 2026; definitive Proxy Statement mailed same day

10-03-2026

ACRES Commercial Realty Corp's total investment portfolio reached $1.96B at December 31, 2025, with CRE whole loans comprising 91.74% ($1.80B net carrying amount). Net interest income declined 19% YoY to $33.2M from $41.2M, driven by a 24% drop in interest income primarily from 25% lower CRE whole loan volumes and yield compression from 9.01% to 7.62%, though offset somewhat by a 26% decrease in interest expense. Positively, real estate income grew 11% to $46.6M and total operating expenses fell 12% to $63.5M, boosted by a $7.7M reversal of credit loss provisions.

• ·Tax loss carryforwards as of 2024 return: REIT QRS operating $32.1M (unlimited life), capital $115.9M (5 years); TRS operating $62.0M (various), capital $20.8M (5 years).
• ·Properties held for sale: $67.5M (3.44% of portfolio) at Dec 31, 2025.
• ·Average yield on CRE whole loans declined from 9.22% in 2024 to 7.67% in 2025.
• ·Management fees - related party down 1% YoY to $6.4M.

10-03-2026

For the nine months ended January 31, 2026, GPO Plus, Inc. reported revenues of $4.1M, up 12% YoY from $3.6M, with gross profit rising 28% to $1.1M driven by improved margins. However, operating expenses surged 21% to $2.6M, resulting in a widened operating loss of $1.5M and net loss of $2.0M versus $1.6M prior year, while Q3 revenues fell 2% YoY to $1.2M and net loss more than doubled to $748K. Cash balances plummeted 95% to $18K from $336K at fiscal year-end, with total assets down 18% to $0.65M amid rising liabilities.

• ·Net cash used in operating activities for nine months: $1.0M (worsened from $0.8M YoY)
• ·Promissory note payable net: $3.4M as of Jan 31, 2026 (up from $2.6M)
• ·Stockholders' deficit worsened to $8.2M from $7.3M
• ·Finance lease right-of-use assets increased to $408K from $206K

10-03-2026

TWFG, Inc. reported total revenues of $248.5M for 2025, up 22% YoY from $203.8M, driven by strong growth in commission income (+20.6%), contingent income (+50%), and TWFG MGA segment (+50.5%). Net income rose 44% to $41.2M, with adjusted net income up to $50.9M (margin 20.5% vs 16.2%), and adjusted diluted EPS of $0.90 (from $0.59); however, organic revenue growth slowed to 11.6% (revised methodology) from 15.2% prior year, reflecting moderated underlying expansion.

• ·Interest expense declined sharply to $287K from $2.2M YoY.
• ·Adjusted EBITDA increased to $66.8M (margin 26.9%) from $45.3M (22.3%).
• ·Diluted EPS $0.53 (from $0.19); legacy organic growth 11.4% vs 14.5% prior.

10-03-2026

M&T Bank Corporation's DEF 14A proxy statement for the 2026 Annual Meeting on April 21, 2026, seeks shareholder approval for electing 12 directors, an advisory vote on 2025 named executive officer compensation, amendment and restatement of the 2019 Equity Incentive Compensation Plan, and ratification of PricewaterhouseCoopers LLP as independent auditors for 2026. As of December 31, 2025, M&T reported strong financial position with $213.5B in total assets, $166.9B in total deposits, $29.2B in shareholders' equity, a 10.84% CET1 capital ratio, and a top-quartile 3.67% net interest margin for the full year. The company highlights its scale as one of the 15 largest U.S. commercial bank holding companies, over 22,000 employees, and more than 900 banking offices, with no material declines or flat metrics disclosed.

• ·Record date for Annual Meeting: February 23, 2026
• ·Advance questions submission deadline: 5:00 p.m. Eastern Time on April 14, 2026
• ·Virtual Annual Meeting access: meetnow.global/MVLYTF9
• ·Proxy materials first available: on or about March 10, 2026

10-03-2026

Walker & Dunlop hosted Investor Day 2026, highlighting its 'Journey to ‘30' strategy targeting $80B+ annual origination volume, $35B+ property sales volume, $2B+ total revenues, and $400-500M adjusted EBITDA. Historical scale-up included employee growth to 1,466 and 46 offices by 2025, with market leadership as #1 Fannie Mae DUS lender, #3 Freddie Mac Optigo, and #4 multifamily broker; however, adjusted EBITDA declined 4% YoY to $316M in 2025 from $329M in 2024 amid rate-driven transaction volume drops (e.g., per banker/broker fell to $141M in 2023 before recovering to $248M). MSR revenue declined due to duration shifts and fee compression despite GSE origination activity.

• ·Debt origination volume dropped to $429B market-wide in 2023 before rising to $634B in 2025 amid rising 10yr UST rates.
• ·#1 Fannie Mae DUS® lender, #3 Freddie Mac Optigo® lender, #2 combined GSE lender, and #4 multifamily broker in 2025.
• ·Institutional CRE AUM for Carlyle, Blackstone, Ares, KKR grew at 28% CAGR, outpacing market 10% CAGR.

10-03-2026

BioNTech SE's FY2025 revenues increased 4% YoY to €2.87B from €2.75B, driven by €613M in new out-licensing revenues, however COVID-19 vaccine revenues declined 18% to €2.0B and other revenues fell 18% to €262M. The company reported a widened net loss of €1.14B versus €665M loss in 2024, with operating loss deepening to €1.40B due to sharply higher other operating expenses of €1.09B, though adjusted net loss narrowed to €117M from a €122M profit. Operating cash flow improved to €456M from €208M amid ongoing investments.

• ·Research and development expenses decreased to €2.10B in FY2025 from €2.25B in FY2024.
• ·Income taxes expense swung to €85.3M in FY2025 from income of €12.4M in FY2024.
• ·Net cash used in investing activities increased to €2.47B in FY2025 from €2.08B in FY2024.
• ·Basic loss per share worsened to €4.70 in FY2025 from €2.77 in FY2024.
• ·Filing date: March 10, 2026 for year ended December 31, 2025.

10-03-2026

Custom Truck One Source, Inc. (CTOS) reported total revenue of $1.94B for FY 2025, up 7.9% YoY from $1.80B, driven by strong rental revenue growth of 14.3% to $506.2M and equipment sales up 6.7% to $1.30B, though parts sales and services declined 2.2% to $133.3M. Gross profit rose 5.5% to $411.9M with fleet utilization improving 6.9% to 79.4%, but operating income dipped 1.1% to $124.9M and net loss widened 8.4% to $31.1M amid higher expenses. Adjusted EBITDA increased 12.9% to $383.6M, while sales order backlog fell 9.1% to $335.3M and net leverage improved to 4.31x from 4.55x.

• ·Ending OEC grew 8.0% YoY to $1.64B; Average OEC on rent up 14.1% to $1.26B.
• ·Depreciation of rental equipment increased 17.5% to $215.6M.
• ·Gain on sale leaseback transaction was $0 in 2025 vs $23.5M in 2024.

10-03-2026

Passage Bio, Inc. terminated its 15-year lease for approximately 62,000 square feet of laboratory space with Hopewell Campus Owner LLC, effective March 4, 2026, following a January 2025 restructuring that ceased operations at the site. The termination required a $4.8M fee plus accrued rent through February 14, 2026, representing a near-term cash outflow. However, the company expects its cash and cash equivalents to fund operations through Q1 2027.

• ·Original Hopewell Lease dated December 15, 2020, with 15-year term from March 2021 commencement.
• ·Lease termination agreement executed March 4, 2026; 8-K filed March 10, 2026.

10-03-2026

Atlas Energy Solutions Inc. (AESI) executed a Global Framework Agreement with Caterpillar Inc. (CAT) for approximately 1.4 gigawatts of incremental power generation assets, with orders scheduled for 2027 through 2029 and aggregate purchase obligations of $840 million. The agreement supports Atlas's private grid development pipeline, with forecasts to own and operate 2.0 gigawatts of power generation assets by 2030. An investor presentation titled 'Long-Term Power Strategy' was posted on the company's IR website.

• ·Orders scheduled for 2027 through 2029
• ·Annual Report on Form 10-K filed with SEC on February 24, 2026

10-03-2026

Q32 Bio Inc. reported net income of $29.8M for FY 2025, a sharp turnaround from a $47.7M net loss in FY 2024, driven by $53.7M in new collaboration revenue and a 60% YoY decline in R&D expenses to $19.2M, while total operating expenses fell 44% to $36.8M. However, cash and equivalents decreased to $48.3M from $77.9M, with net cash used in operations improving to $33.5M from $67.7M but still reflecting ongoing burn, and G&A expenses remained essentially flat at $17.7M.

• ·Basic EPS $2.42 FY2025 vs ($5.12) FY2024
• ·Gain on sale of asset $11.7M in FY2025
• ·Venture debt total $9.7M as of Dec 31 2025 (current $6.2M)
• ·Weighted-average common shares basic 12.3M FY2025 vs 9.3M FY2024
• ·Total assets $61.8M Dec 31 2025 vs $92.3M Dec 31 2024

10-03-2026

Cullinan Therapeutics reported a widened net loss of $219.9M in 2025, up 31% YoY from $167.6M in 2024, driven by a 31% increase in R&D expenses to $187.4M while G&A expenses remained essentially flat at $54.2M. Total operating expenses rose 23% to $241.6M, and total assets declined 28% to $448.4M amid reduced investments, though cash and equivalents increased 6% to $88.3M. Operating cash burn intensified 21% to $175.8M used, offset by $180.0M net cash from investing activities.

• ·Equity-based compensation expense was $36.0M in 2025, down slightly from $37.8M in 2024.
• ·Long-term investments declined to $58.3M from $204.4M as of Dec 31, 2025.
• ·Common stock shares issued and outstanding increased to 60.2M from 58.5M.

10-03-2026

Rapport Therapeutics, a clinical-stage biotech, reported a widened net loss of $111.5M for the year ended December 31, 2025, up 42% YoY from $78.3M in 2024, primarily due to sharply higher operating expenses with R&D surging 56% to $94.8M and G&A rising 37% to $30.3M. However, the company bolstered its balance sheet through strong financing inflows of $270.8M (up from $221.6M), driving total assets to $512.4M (up 63%) and short-term investments to $437.9M (up 76%), while cash and equivalents dipped slightly to $52.6M. Net cash used in operations increased to $87.5M from $64.8M, reflecting ongoing R&D investments.

• ·Net loss per share improved to -$2.86 from -$3.78 YoY due to increased share count.
• ·Stockholders’ equity grew to $484.7M from $305.4M.
• ·Common shares issued and outstanding increased to 47.8M from 36.6M, including 11.1M from underwritten public offering.
• ·Stock-based compensation expense rose to $18.9M from $10.2M.

10-03-2026

dMY Squared Technology Group, Inc. filed a Form 425 on March 10, 2026, furnishing a press release announcing milestones in Horizon Quantum's business and the ongoing business combination originally agreed on September 9, 2025, while inviting interested parties to a live X Spaces event. The transaction includes a planned PIPE of approximately $111.9M in Holdco’s Class A ordinary shares, with the Registration Statement effective February 17, 2026, and proxy statement mailed the same day. The filing emphasizes extensive risks, including potential termination of the agreement, failure to close the PIPE, shareholder approval issues, and operational challenges for Holdco's quantum technologies.

• ·Business Combination Agreement dated September 9, 2025.
• ·Registration Statement on Form F-4 effective February 17, 2026.
• ·Definitive proxy statement/prospectus mailed to dMY shareholders on February 17, 2026, for Special Meeting vote.
• ·Warrants exercisable at $11.50 per share of Class A common stock.
• ·dMY Annual Report on Form 10-K for FY ended December 31, 2024, filed April 3, 2025.

10-03-2026

U.S. Gold Corp. (USAU) filed its DEF 14A proxy statement dated March 10, 2026, for the virtual annual stockholder meeting on April 27, 2026, at 9:00 a.m. MT, soliciting votes on director elections (Proposal 1) and auditor ratification (Proposal 2). As of the record date of February 26, 2026, there were 16,501,163 shares of common stock outstanding. The filing includes sections on corporate governance, director compensation, executive officer details, pay versus performance disclosures for fiscal years ended April 30, 2023-2025, and security ownership, with no specific compensation amounts or performance variances detailed in the provided content.

• ·Annual Meeting held virtually at www.usgold.vote
• ·Proxy materials available online at www.usgold.vote; Notice of Internet Availability mailed on or about March 10, 2026
• ·Fiscal year-end disclosures cover periods May 1, 2022-April 30, 2025 for pay vs. performance (PEO and Non-PEO NEOs)
• ·Company address: 1910 East Idaho Street, Suite 102-Box 604, Elko, Nevada 89801

10-03-2026

Domino's Pizza, Inc. issued its DEF 14A proxy statement dated March 10, 2026, for the virtual 2026 Annual Meeting on April 21, 2026, at 10:00 a.m. ET, with record date February 25, 2026. Agenda includes electing eight director nominees for one-year terms, ratifying PricewaterhouseCoopers LLP as auditors for fiscal 2026, advisory vote on named executive officer compensation, and two shareholder proposals. The statement highlights 2025 progress on the 'Hungry for MORE' strategy and addition of two new board members, alongside pay versus performance disclosures for PEOs Russell J. Weiner and former PEO Richard E. Allison Jr.

• ·Virtual meeting exclusively online at www.virtualshareholdermeeting.com/DPZ2026; requires 16-digit control number for admission
• ·Two new members welcomed to Board of Directors during 2025
• ·2025 Annual Report available at ir.dominos.com and http://materials.proxyvote.com/25754A
• ·Pay versus performance disclosures include changes in fair value of outstanding and unvested equity awards for multiple years (2021-2025)

10-03-2026

Terrell Kirk Crews II, Executive Vice President and Chief Risk Officer of NextEra Energy, Inc., notified the company of his resignation effective March 20, 2026, to accept a chief financial officer position with another company. NextEra Energy thanked Mr. Crews for his leadership and contributions. No information on a successor or impact to operations was provided.

• ·Resignation notification date: March 5, 2026
• ·8-K filing date: March 10, 2026

10-03-2026

Harvard Bioscience, Inc. entered into an amended employment agreement with CEO John Duke effective March 6, 2026, providing a $515,000 annual base salary, a $100,000 cash bonus upon successful credit facility refinancing, up to 80% incentive compensation, and a target 75,000 RSUs for 2026 post 1:10 reverse stock split. The Board appointed Mark Frost as permanent CFO and Treasurer, effective the same date, with a $375,000 base salary, up to 60% incentive compensation, and target 30,000 RSUs for 2026 post reverse stock split. Both agreements supersede prior ones and include severance benefits for certain termination events.

• ·Duke agreement term extends to July 16, 2027, with automatic two-year renewals.
• ·Frost agreement term extends to April 10, 2027, with automatic two-year renewals.
• ·Duke prior agreement dated July 16, 2025; Frost prior agreement dated April 10, 2025.
• ·Reverse stock split (1:10) effective March 13, 2026.
• ·Frost served as Interim Financial Officer from April 10, 2025, to March 6, 2026.

10-03-2026

TENAX Therapeutics reported a significantly widened net loss of $52.6M for the year ended December 31, 2025, up 199% from $17.6M in 2024, driven by R&D expenses surging 157% to $32.7M and G&A expenses rising 249% to $23.7M, resulting in total operating expenses increasing 189% to $56.4M. While cash and equivalents grew slightly to $97.6M from $94.9M and interest income doubled to $3.8M, operating cash burn accelerated to $35.8M from $14.8M, with financing inflows dropping sharply to $38.5M from $99.9M. Stockholders' equity rose modestly to $97.1M amid increased share count to 9.3M outstanding.

• ·Net loss per share worsened to $(1.34) from $(1.15).
• ·Weighted average shares outstanding increased to 39.2M from 15.3M.
• ·Stock-based compensation expense rose to $19.2M from $1.1M.
• ·Common shares issued via public offering net proceeds: $23.2M in 2025 vs $100.3M in 2024.

10-03-2026

Adani Enterprises Limited's wholly-owned subsidiary, Adani Road Transport Limited (ARTL), completed the acquisition of the remaining 49% equity share capital and 100% optionally convertible redeemable preference shares in D P Jain TOT Toll Roads Private Limited (DPJ TOT) on March 10, 2026, making DPJ TOT a wholly-owned subsidiary of ARTL at an enterprise value of ₹1,342 Cr as of September 30, 2025. This strategic move expands Adani's footprint in road infrastructure, aligning with its development objectives. DPJ TOT's turnover grew from ₹122 Cr in FY23 to ₹147 Cr in FY25 (17.2% YoY in FY24 but only 2.8% YoY in FY25, indicating flat recent performance).

• ·DPJ TOT incorporated on May 6, 2021
• ·Transaction executed at arm's length per SPA dated September 12, 2025
• ·Earlier 51% equity acquisition completed February 10, 2026
• ·All requisite governmental/regulatory approvals received
• ·Cash consideration paid, subject to closing adjustments

10-03-2026

Godavari Biorefineries Limited disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015, that their Japanese patent application No. 2022-568620, titled 'Use of Compounds for Treating Viral Infections,' has been granted by the Japan Patent Office on March 10, 2026. The patent covers compounds for inhibiting V-ATPase activity in cells and methods for treating viral infections, strengthening the company's intellectual property portfolio in antiviral therapeutics.

• ·Script Symbol: GODAVARIB
• ·Script Code: 544279
• ·Manoj Jain Membership No. F-7998

10-03-2026

Artemis Electricals and Projects Limited has received NSE approval (letter NSE/LIST/246 dated March 10, 2026) for listing 25,10,36,900 equity shares of Re. 1/- each fully paid up on the NSE Main Board, effective March 12, 2026. The company has intimated BSE pursuant to SEBI LODR Regulations. This marks the completion of the IPO listing process with no financial performance data disclosed.

• ·Stock Symbol: AEPL (EQ series)
• ·Face Value: Re. 1/- each fully paid up
• ·CIN: L51505MH2009PLC196683
• ·Registered Office: Artemis Complex, Gala no 105 & 108, National Express Highway, Vasai (East), Thane, MH 401208

10-03-2026

Setubandhan Infrastructure Limited, undergoing CIRP since November 28, 2022 initiated by State Bank of India, held an RP meeting on December 1, 2025, to note the delay in submitting audited FY25 standalone financial results beyond the 60-day deadline, attributed to suspended management's failure to provide books and records. FY25 results show turnover of ₹23.22 L, total expenditure of ₹1.74 Cr, and net loss of ₹1.51 Cr, with total assets and liabilities both at ₹169.70 Cr and net worth of ₹45.14 Cr; however, the audit carries multiple qualified opinions including unconfirmed balances, unrevalued assets, missing bank confirmations, and disclaimer on subsidiaries and related parties. A CoC-approved resolution plan was rejected by NCLT Mumbai on March 24, 2025, with an appeal pending before NCLAT since July 9, 2025.

• ·Audit qualifications are repetitive since FY23 for most items, including qualified opinion on balance confirmations, liabilities not restated per CIRP claims, assets not revalued, no bank statements for certain accounts, disclaimer on subsidiaries' CARO reports, and related party transactions not disclosed.
• ·EPS for FY25: (₹0.15).
• ·RP's AFA valid up to December 31, 2026.
• ·NSE Symbol: SETUINFRA; BSE Scrip Code: 533605.

10-03-2026

10-03-2026

10-03-2026

Aster DM Healthcare Limited held an equity shareholders' meeting on March 10, 2026, at 10:00 A.M. IST via VC/OAVM, as directed by the NCLT Hyderabad bench's order dated January 21, 2026, to consider and approve the Scheme of Amalgamation with Quality Care India Limited. The meeting, chaired by Advocate Ms. Sandhya Rani, was attended by 64 members, with remote e-voting from March 6 to March 9, 2026, and e-voting during the meeting; results are to be announced later. Ms. Alisha Moopen addressed the salient features of the scheme and responded to shareholder queries.

• ·NCLT Order dated January 21, 2026, directing the meeting
• ·Remote e-voting period: March 6, 2026 (9:00 A.M.) to March 9, 2026 (5:00 P.M.)
• ·Meeting concluded at 10:55 A.M. IST
• ·Disclosure pursuant to Regulation 30 of SEBI Listing Regulations